ApicHope(SZ:300723) Zheng Quan Shi Bao Wang·2025-06-17 04:13Core Insights - The upcoming EULAR conference in Barcelona will showcase innovative research on the gout drug AR882 by Yipinhong, attracting over 130 countries' experts in rheumatology [1] - AR882 is a next-generation URAT1 inhibitor that promotes uric acid excretion and avoids renal toxicity, with a once-daily dosing regimen [1][2] - The drug has received Fast Track Designation from the FDA for gout stone research, potentially filling a gap in oral medications for gout stone treatment [1] Group 1 - AR882 is currently in global Phase III clinical trials, with over a thousand participants enrolled [2] - The drug demonstrates three breakthrough therapeutic effects: precise uric acid control, dissolution of gout stones, and safety without renal toxicity [2] - Clinical data shows that AR882 can significantly reduce uric acid crystal volume and achieve complete dissolution of at least one target gout stone [2][3] Group 2 - In an 18-month treatment period, AR882 showed good tolerability with no clinically significant adverse events or laboratory abnormalities [2] - Patients treated with AR882 maintained serum uric acid levels at clinically meaningful levels of less than 4 mg/dL [3] - The high response rate for complete dissolution of gout stones and rapid reduction in uric acid crystal volume indicates a significant improvement in patients' quality of life [2]